Observational studyFrontiers in immunology2025
Prognostic value of liver stiffness measurement for complications after allogeneic transplant with post-transplant cyclophosphamide.
Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pre-existing comorbidities prior to allogeneic hematopoietic stem cell transplantation (HSCT), significantly affects outcomes. Prior hepatic impairment is included in classic prognostic scores like HCT-CI, without taking into consideration modern assessment techniques such as liver stiffness (LS) measurement. We aimed to evaluate the value of LS using Fibroscan (FS) to predict transplant outcomes and hepatic complications in patients undergoing allo-HSCT using post-transplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. Methods: We conducted a single-center, prospective, observational study to evaluate the utility of LS measurement performed prior to transplantation and on day +14 to predict transplant outcomes, between October 2021 and March 2024. ROC curves were used to identify cut-off points for LS values for the development of hepatotoxicity, veno-occlusive disease (VOD), and hepatic acute and chronic GVHD. Logistic regression was used to analyse the impact of LS on overall survival (OS), event-free survival (EFS), non-relapse mortality (NRM) and graft-versus-host-disease and relapse-free survival (GRFS) . Results: One hundred eight patients were included. Median follow-up was 12.5 months. OS, EFS, GRFS, cumulative incidence of relapse and NRM at 12-months were 75%, 68%, 55%, 22% and 9%, respectively. Cumulative incidences of grade II-IV acute GVHD at day 180 and moderate-severe chronic GVHD at 12 months were 14% and 12%, respectively. Five patients (4.6%) developed VOD. LS variation (FSΔ) from baseline LS to day +14 was significantly increased in those patients who developed VOD compared to those who did not (p=0.048; AUROC 0.8). Logistic regression univariate analysis showed FS+14>6KPa to be predictive for worse OS and EFS (p<0.05). Multivariate analysis found FS+14>6 KPa to be predictive for worse EFS. Discussion: In our experience, increase in LS between baseline and day +14 was predictive for VOD. In addition, a measurement of FS+14>6Kpa was predictive for the outcome of allo-HSCT, with an independently predictive value for worse EFS. Thus, FS+14>6 KPa should be considered in future prognostic models used for PTCY-based HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.